Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Stem Cells. Oct 26, 2025; 17(10): 112434
Published online Oct 26, 2025. doi: 10.4252/wjsc.v17.i10.112434
Published online Oct 26, 2025. doi: 10.4252/wjsc.v17.i10.112434
Recombinant human thrombopoietin in pediatric allogeneic hematopoietic stem cell transplantation: Clinical insights and future directions
Lu Cui, Jian-Chuan Deng, Nan Zhang, Department of Hematology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China
Co-corresponding authors: Jian-Chuan Deng and Nan Zhang.
Author contributions: Cui L collected and reviewed the literature, drafted the manuscript, and contributed to the data interpretation; Deng JC conceptualized the study, provided critical revisions to the manuscript, and supervised the overall project; Zhang N designed the study, critically reviewed the manuscript for important intellectual content, and provided supervision. Deng JC and Zhang N jointly supervised the work as co-corresponding authors. All authors read and approved the final version of the manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Nan Zhang, MD, PhD, Department of Hematology, The Second Affiliated Hospital of Chongqing Medical University, No. 288 Tianwen Avenue, Nan’an District, Chongqing 400010, China. zhangnan@hospital.cqmu.edu.cn
Received: July 28, 2025
Revised: September 2, 2025
Accepted: September 15, 2025
Published online: October 26, 2025
Processing time: 90 Days and 10.8 Hours
Revised: September 2, 2025
Accepted: September 15, 2025
Published online: October 26, 2025
Processing time: 90 Days and 10.8 Hours
Core Tip
Core Tip: This cohort study evaluates the safety and efficacy of recombinant human thrombopoietin (rhTPO) in pediatric allogeneic hematopoietic stem cell transplantation. The findings suggest that rhTPO promotes earlier platelet engraftment, particularly in younger children aged 0-9 years. This age-dependent response highlights the influence of developmental hematopoiesis on treatment outcomes. Despite the limitations of a single-center, non-randomized design, the study provides novel insights that support rhTPO as a promising supportive therapy in pediatric allogeneic hematopoietic stem cell transplantation and underscores the need for age-specific post-transplant strategies.